THE BE T
Multimedia Highlights
From the CardioSource WorldNews YouTube Channel | Scan the QR code to watch the full video
Making Sense of Conflicting Data:
Neurologic Events in SAVR and TAVR
Philippe Genereux, MD: “What we know is that
before the TAVR era, the data on stroke after
surgical aortic valve replacement were very scant.
Part of the reason was that the education was not
really systematic and was mainly site report.”
Sex Differences and Response to PCI in
Acute Myocardial Infarction: OCTAVIA
Study
Giulio Guagliumi, MD: “I think [the sex differences]
are an important topic because of the increasing
number of women coming to the hospital
searching for care with acute MI. All of the data we
have are very focused on and mainly derive from
[studies of] men. That is an issue because when
you are running bigger studies and you don’t
have enough [women] coming in, you can’t tell the
differences.”
Single Breath-hold Compressed
Sensing Strategy: Pote ntial to Replace
Standard Cardiac MR
Juerg Schwitter, MD: “We were just looking at left
ventricular function in this paper, and it showed
that if the data are registered in space with respect
to respiratory motion, we are more precise than
with techniques that we have today.”
Guagliumi G, et al. J Am Coll Cardiol
Vincenti G, et al. J Am Coll Cardiol Img.
Intv. 2014;7:958-68.
2014;7:882-92.
The Impact of ARBs on HFpEF with
Worsening Renal Function
Quadripolar Leads: The Future of
CRT-D or a Lead Too Far?
Stuart J. Pocock, PhD: “There is a whole history of
effective, good clinical trials researching drugs. In
the States for a long time, it was felt that the device
trial methodology was lagging 10 years behind.
The situation is worse in Europe. To get a new
cardiovascular device approved in Europe, you do
not have to do randomized trials. You just need to
do a short-term registry with a limited number of
patients and the device will likely get approved.”
Kevin Damman, MD, PhD: “We now begin to
realize that not all of these incremental changes
in creatinine give a worse outcome. We tend to
think that when an ACE-inhibitor is started you can
accept some increase in creatinine, but for HF with
preserved ejection fraction (HFpEF) it’s different
because we don’t have any randomized controlled
trials that show any benefit from any treatment.”
Rachel J. Lampert, MD: “Basically, the quadripolar lead allows you to put the lead far out into
the apex, where you don’t necessarily want to
pace, but you can put the lead far out where you
can get stability. From there, you can pace from
a more basal location using the more proximal
electrodes. So I think all of the quadripolar leads
are really going to be a big advantage.”
Pocock S, Gersh B. J Am Coll Cardiol.
Damman K, et al. J Am Coll Cardiol.
2014;64:1615-28.
2014;64:1106-13.
Do Current Clinical Trials Meet
Society’s Needs?
22
CardioSource WorldNews
December 2014